Reversible Dementia with Parkinsonian Features Associated with Budesonide Use
Neurol 67:723, Proda,C.I.,et al, 2006
Atypical Antipsychotics in the Elderly with Parkinson Disease and the "Black Box" Warning
Neurol 67:564-566, Friedman,J.H., 2006
Common Misdiagnosis of a Common Neurological Disorder: How Are We Misdiagnosing Essential Tremor?
Arch Neurol 63:1100-1104, Jain,S.,et al, 2006
Collaborative Analysis of a-Synuclein Gene Promotor Variability and Parkinson Disease
JAMA 296:661-670, Maraganore,D.M.,et al, 2006
Restless Legs Syndrome: Is Treatable But Under-Recognised
BMJ 333:457-458, Medcalf,P. &Bhatia,K.P., 2006
Parkinsons Disease and Genetics
The Neurologist 12:240-244, Lester,J.&Otero-Siliceo,E., 2006
Efficacy and Safety of Pramipexole in Restless Legs Syndrome
Neurol 67:1034-1039, Winkelman,J.W.,et al, 2006
Efficacy of Cabergoline in Restless Legs Syndrome, A Placebo-Controlled Study with Polysomnography (CATOR)
Neurol 67:1040-1046, Oertel,W.H.,et al, 2006
Pallidal Deep-Brain Stimulation in Primary Generalized or Segmental Dystonia
NEJM 355:1978-1990, Kupsch,A.,et al, 2006
Genetics of Parkinsons Disease and Parkinsonism
Ann Neurol 60:389-398, Hardy,J.,et al, 2006
Impaired Visual Search in Drivers with Parkinsons Disease
Ann Neurol 60:407-413,387, Uc,E.Y.,et al, 2006
Parkinsons Disease with Camptocormia
JNNP 77:1223-1228,1205, Bloch,F.,et al, 2006
Dopamine Agonists and Cardiac Valvulopathy in Parkinson Disease: A Case-Control Study
Neurol 67:1225-1229, Yamamoto,M.,et al, 2006
Brain Metal Concentrations in Chronic Liver Failure Patients With Pallidal T1 MRI Hyperintensity
Neurol 67:1984-1989, Klos,K.J.,et al, 2006
Acromegaly
NEJM 355:2558-2573, Melmed,S., 2006
Dopamine-Responsive Dystonia
eMedicine (Apr), Nikhar,N.K., 2006
The role of radiotracer imaging in Parkinson disease
Neurol 64:208-215, Ravina, B., et al, 2005
Amorphine-induced eosinophilic panniculitis and hypereosinophilia in Parkinson disease
Neurol 64:392-393, Pot, C., et al, 2005
Bilateral Deep-Brain Stimulation of the Globus Pallidus in Primary Generalized Dystonia
NEJM 352:5 459-467, 498, Vidailhet, M., et al, 2005
Quantatative Assessment of Driving Performance in Parkinson's Disease
JNNP 76:176-180, 159, Wood, J.M., et al, 2005
Genetic Screening for a Single Common LRRK2 Mutation in Familial Parkinson's Disease
Lancet 365:410-412, Nichols, W.C., et al, 2005
A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Arch Neurol 62:241-248, The PRESTO Study, 2005
"Levodopa Phobia": A New Iatrogenic Cause of Disability in Parkinson Disease
Neurol 64:923-924, Kurlan, R., 2005
The Serotonin Syndrome
NEMJ 352:1112-20, Boyer, E.W. & Shannon, M., 2005
Rasagiline as an Adjunct to Levodopa in Patients With Parkinsons Disease and Motor Fluctuations (LARGO, Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily, Study)
Lancet 365:947-954, 914, Rascol,O., et al, 2005
Identification of Embolic Stroke Patterns by Diffusion-Weighted MRI in Clinically Defined Lacunar Stroke Syndromes
Stroke 36:757-761, Wessels,T.,et al, 2005
Pallidal vs Subthalamic Nucleus Deep Brain Stimulation in Parkinson Disease
Arch Neurol 62:554-560,533, Anderson,V.C.,et al, 2005
Pallidal Stimulation Improves Pantothenate Kinase-Associated Neurodegeneration
Ann Neurol 57:738-741,613, Castelnau,P.,et al, 2005
Tourettes Syndrome and Deep Brain Stimulation
JNNP 76:992-995, Houeto,J.L.,et al, 2005
Donepezil for Dementia in Parkinsons Disease: A Randomised, Double Blind, Placebo Controlled, Crossover Study
JNNP 76:934-939,903, Ravina,B.,et al, 2005
Short-Term Paroxetine Treatment Does Not Alter the Motor Response to Levodopa in PD
Neurol 64:1797-1798, Chung,K.A.,et al, 2005
Spontaneous CSF Leak Treated with Percutaneous CT-Guided Fibrin Glue
Neurol 64:1818-1819, Gladstone,J.P.,et al, 2005
[99mTc]TRODAT-1 SPECT Imaging Correlates with Odor Identification in Early Parkinson Disease
Neurol 64:1716-1720, Siderowf,A.,et al, 2005
Isolated Monoparesis Following Stroke
JNNP 76:805-807, Paciaroni,M.,et al, 2005
Searching for a Relationship Between Manganese and Welding and Parkinsons Disease
Neurol 64:2021-2028, 2001, Jankovic,J., 2005
Neurologic Manifestations in Welders with Pallidal MRI T1 Hyperintensity
Neurol 64:2033-2039,2001, Josephs,K.A.,et al, 2005
New and Reliable MRI Diagnosis for Progressive Supranuclear Palsy
Neurol 64:2050-2055, Oba,H.,et al, 2005
Pleuropulmonary Fibrosis After Long-term Treatment With the Dopamine Agonist Pergolide for Parkinson Disease
Arch Neurol 62:1290-1295, Tintner,R.,et al, 2005
Sudden Uncontrollable Somnolence and Medication Use in Parkinson Disease
Arch Neurol 62:1242-1248, Avorn,J.,et al, 2005
Camptocormia
Neurol 65:355-359, Azher,S.N. &Jankovic,J., 2005
Initial Diagnoses Given to Persons with the Fragile X Associated Tremor/Ataxia Syndrome (FXTAS)
Neurol 65:299-301, Hall,D.A.,et al, 2005
The Role of Levodopa in the Management of Dementia With Lewy Bodies
JNNP 76:1200-1203, Moloy,S.,et al, 2005
Cluster Headache:Pathogenesis,Diagnosis, and Management
Lancet 366:843-855, May,A., 2005
Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005
Science and Ethics of Sham Surgery, A Survey of Parkinson Disease Clinical Researchers
Arch Neurol 62:1357-1360,1343, Kim,S.Y.H.,et al, 2005
Neurologic Spectrum of Chronic Liver Failure and Basal Ganglia T1 Hyperintensity on Magnetic Resonance Imaging, Probably Manganese Neurotoxicity
Arch Neurol 62:1385-1390, Klos,K.J.,et al, 2005
Pathological Gambling Caused by Drugs Used to Treat Parkinson Disease
Arch Neurol 62:1377-1381, Dodd,M.L.,et al, 2005
Contribution of Atrial Fibrillation to Incidence and Outcome of Ischemic Stroke
Stroke 36:1115-1119, Marini,C.,et al, 2005
Neuropathology of Dementia in Parkinsons Disease: A Prospective, Community-Based Study
Ann Neurol 58:773-776,663, Aarsland,D.,et al, 2005
Cabergoline-Related Severe Restrictive Mitral Regurgitation
NEJM 353:1974-1975, Rosen,C.J., 2005